Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones. WATER ...

Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Read More on ITOS: ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

This page features the latest news about the Iteos stock. Iteos Therapeutics stock hits 52-week low at $8.49 Iteos Therapeutics Inc. (NASDAQ: ITOS) stock has reached a 52-week low, touching down ...

Domvanalimab (dom). The company’s most advanced asset is dom, an Fc-silent anti-TIGIT monoclonal antibody that is undergoing evaluation in three registrational trials for the treatment of ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus ...

Former Democratic congresswoman Tulsi Gabbard has been appointed as the director of national intelligence by US President-elect Donald Trump. Gabbard, who switched to the Republican Party, is a ...